Drugs / Amorphous Calcium Carbonate
Amorphous Calcium Carbonate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02864784 | Jun 2022 → Dec 2023 | castration-resistant prostate carcinoma | Amorphical Ltd. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03582280 | Jul 2018 → Jun 2022 | — | Amorphical Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03057314 | Jun 2017 → Dec 2019 | cancer | Amorphical Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04900337 | Feb 2021 → Jun 2023 | COVID-19 | Amorphical Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06547151 | Dec 2024 → Sep 2026 overdue | hypoparathyroidism | Amorphical Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amorphous Calcium Carbonate | “This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo...” NCT04900337 ↗4“This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia...” NCT06547151 ↗ |
| Known as | ACC | “This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo...” NCT04900337 ↗1“This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia...” NCT06547151 ↗ |
| Known as | AMOR-1 | “This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia...” NCT06547151 ↗ |
| Route | Oral | “Administered Orally” NCT03057314 ↗ |